Rashmi Kanagal‐Shamanna

This study uses spatial proteomics to reveal that TP53 mutant AML residual disease forms immunosuppressive niches in the bone marrow, segregated from T-cells, suggesting niche-level immune evasion.

This study examines how chemotherapy affects clonal diversity and mutation patterns in hematopoietic stem cells, finding that melphalan increases mutational burden and promotes clonal aging, potentially leading to therapy-related myeloid neoplasms.

This study shows MDS hematopoietic stem cells reprogram their differentiation state to bypass venetoclax sensitivity through genetic mutations and transcriptional changes.

This study evaluates Optical Genome Mapping (OGM) for detecting structural variants in myeloid neoplasms, showing high concordance and identifying additional clinically relevant variants compared to standard of care methods.

This study shows that IL-1B-mediated inflammation drives ineffective erythropoiesis in early-stage MDS and that canakinumab can reduce transfusion dependence in patients with DNMT3A and TET2 mutations.

The paper describes the evolution of the CIViC knowledgebase to meet the needs of the cancer variant interpretation community by expanding its functionality and data types.

This study evaluates optical genome mapping's ability to detect chromosomal variants in MDS patients, showing high concordance with standard methods and identifying additional clinically relevant aberrations.

This study evaluates optical genome mapping (OGM) for detecting genomic aberrations in AML, finding it identifies all clinically relevant SVs and CNVs and detects additional variants missed by standard methods.